{"id":4490,"date":"2025-09-16T12:21:35","date_gmt":"2025-09-16T09:21:35","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4490"},"modified":"2025-09-16T12:31:54","modified_gmt":"2025-09-16T09:31:54","slug":"givinostat-duvyzat-distribution-brazil","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/givinostat-duvyzat-distribution-brazil\/","title":{"rendered":"Italfarmaco e Multicare Pharma assinam acordo de distribui\u00e7\u00e3o exclusiva para Givinostat (Duvyzat), um tratamento para DMD no Brasil"},"content":{"rendered":"<p class=\"wp-block-paragraph\">A Italfarmaco anunciou um acordo exclusivo com a Multicare Pharma, uma importante empresa farmac\u00eautica na Am\u00e9rica Latina. <strong>A Multicare Pharma apoiar\u00e1 a aprova\u00e7\u00e3o regulat\u00f3ria no Brasil e distribuir\u00e1 o givinostat (Duvyzat), o novo inibidor da histona desacetilase (HDAC) da Italfarmaco para tratar a distrofia muscular de Duchenne (DMD).<\/strong> De acordo com os termos do acordo, a Multicare gerenciar\u00e1 as opera\u00e7\u00f5es de fornecimento e distribui\u00e7\u00e3o do medicamento no Brasil. N\u00e3o foram divulgados termos financeiros. \u2013 Leia: <a href=\"https:\/\/dmdwarrior.com\/pt\/duvyzat-givinostat-nonsteroidal-drug\/\" data-type=\"post\" data-id=\"3957\">O que \u00e9 Duvyzat?<\/a> \u2013<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cNa Italfarmaco, nosso compromisso com as doen\u00e7as raras norteia todas as nossas decis\u00f5es. O acesso ao givinostat pode ter um impacto significativo para pacientes com DMD no Brasil\u201d, afirmou Antonio Nardi, Vice-Presidente e Chefe de Desenvolvimento de Neg\u00f3cios e Portf\u00f3lio da Italfarmaco. \u201cA parceria com a Multicare, l\u00edder na \u00e1rea de doen\u00e7as raras e de alta complexidade com ampla atua\u00e7\u00e3o em todo o Brasil, nos permite levar este tratamento inovador \u00e0queles que mais precisam.\u201d<\/p>","protected":false},"excerpt":{"rendered":"<p>Italfarmaco announced an exclusive agreement with Multicare Pharma, a prominent pharmaceutical company in Latin America. Multicare Pharma will support the regulatory approval in Brazil and distribute givinostat (Duvyzat), Italfarmaco\u2019s novel histone deacetylase (HDAC) inhibitor to treat Duchenne muscular dystrophy (DMD). According to the terms of the agreement, Multicare will manage supply and distribution operations for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4491,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[82,46,47,311,420],"class_list":["post-4490","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-brazil","tag-duvyzat","tag-givinostat","tag-italfarmaco","tag-multicare-pharma"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/4490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=4490"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/4490\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/4491"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=4490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=4490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=4490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}